MedTrace Logo

12-Week Study in Adult Subjects With Asthma

NCT01516073 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 629

Last updated 2014-12-11

No results posted yet for this study

Summary

This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.

Conditions

Interventions

DRUG

Fluticasone Propionate

FP BID for 12 weeks

Sponsors & Collaborators

  • Dey

    lead INDUSTRY

Principal Investigators

  • Imtiaz Chaudry · Dey Pharma, L.P.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516073 on ClinicalTrials.gov